文献速递肝病消化道肿瘤与早癌

等待肝移植的肝细胞癌患者的治疗:系统综述与荟萃分析

Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
PubMed 文献 · Hepatology · 2017-11-29

该系统综述与荟萃分析检索1996年至2016年4月25日的多个数据库,纳入等待肝移植的肝硬化肝细胞癌成人患者,评估桥接或降期治疗(包括经导管动脉化疗栓塞、经动脉放射栓塞、消融和放疗)的效果。未发现随机对照试验;对于T1期患者仅有两项高偏倚风险的非随机比较研究;对于T2期患者,任何桥接治疗相比无治疗在等待名单脱落风险上无显著降低;对于初始T3期接受降期治疗的患者,移植后1年和5年生存率显著提高。总体证据质量极低。

要点

  • 等待肝移植的肝细胞癌患者接受局部区域治疗,在等待名单脱落和移植后结局方面呈现无显著趋势。
  • T2期患者接受桥接治疗相比无治疗,因进展导致等待名单脱落的相对风险为0.32(95%CI 0.06-1.85;I²=0%),无显著差异。
  • 初始T3期患者接受降期治疗后,移植后1年生存率相对风险1.11(95%CI 1.01-1.23),5年生存率相对风险1.17(95%CI 1.03-1.32),显著提高。

核心结论

  • 对于等待肝移植的肝细胞癌患者,使用局部区域治疗与等待名单和移植后结局改善的无显著趋势相关,但现有证据存在高选择偏倚风险。

研究设计与样本

  • 系统综述与荟萃分析,检索1996年至2016年4月25日的多个数据库,纳入等待肝移植的肝硬化肝细胞癌成人患者,治疗包括桥接或降期治疗,疗法包括经导管动脉化疗栓塞、经动脉放射栓塞、消融和放疗,纳入比较性和非比较性研究,未发现随机对照试验。

主要发现

  • 对于T1期肝细胞癌等待肝移植的成人,仅有两项高偏倚风险的非随机比较研究;一项系列中接受局部区域治疗的患者6个月全因脱落率为5.3%,另一系列未接受局部区域治疗的患者中位随访2.4年时脱落率为30%,进展至T2期肝细胞癌的比例为88%。
  • 对于T2期肝细胞癌等待肝移植的成人,基于三项比较性研究,任何桥接治疗相比无治疗,因进展导致等待名单脱落的相对风险为0.32(95%CI 0.06-1.85;I²=0%),全因等待名单脱落的相对风险为0.38(95%CI 0.060-2.370;I²=85.7%),均无显著差异。
  • 有五项比较性研究报告移植后生存率,十项比较性研究报告移植后复发,两个终点均未见显著差异。
  • 对于初始T3期肝细胞癌接受局部区域治疗的成人,三项研究报告任何降期治疗相比无降期治疗,接受局部区域治疗的患者移植后1年生存率相对风险为1.11(两项研究;95%CI 1.01-1.23),5年生存率相对风险为1.17(一项研究;95%CI 1.03-1.32),显著提高。

局限性

  • 证据质量极低,原因包括高偏倚风险、不精确和不一致性。
  • 对于T3期降期治疗的分析,证据质量极低,原因包括严重偏倚风险和不精确。
  • 现有证据存在高选择偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Patients with hepatocellular carcinoma (HCC) who are listed for liver transplantation (LT) are often treated while on the waiting list with locoregional therapy (LRT), which is aimed at either preventing progression of HCC or reducing the measurable disease burden of HCC in order to receive increased allocation priority. We aimed to synthesize evidence regarding the effectiveness of LRT in the management of patients with HCC who were on the LT waitlist. We conducted a comprehensive search of multiple databases from 1996 to April 25, 2016, for studies that enrolled adults with cirrhosis awaiting LT and treated with bridging or down-staging therapies before LT. Therapies included transcatheter arterial chemoembolization, transarterial radioembolization, ablation, and radiotherapy. We included both comparative and noncomparative studies. There were no randomized controlled trials identified. For adults with T1 HCC and waiting for LT, there were only two nonrandomized comparative studies, both with a high risk of bias, which reported the outcome of interest. In one series, the rate of dropout from all causes at 6 months in T1 HCC patients who underwent LRT was 5.3%, while in the other series of T1 HCC patients who did not receive LRT, the dropout rate at median follow-up of 2.4 years and the progression rate to T2 HCC were 30% and 88%, respectively. For adults with T2 HCC awaiting LT, transplant with any bridging therapy showed a nonsignificant reduction in the risk of waitlist dropout due to progression (relative risk [RR], 0.32; 95% confidence interval [CI], 0.06-1.85; I2 = 0%) and of waitlist dropout from all causes (RR, 0.38; 95% CI, 0.060-2.370; I2 = 85.7%) compared to no therapy based on three comparative studies. The quality of evidence is very low due to high risk of bias, imprecision, and inconsistency. There were five comparative studies which reported on posttransplant survival rates and 10 comparative studies which reported on posttransplant recurrence, and there was no significant difference seen in either of these endpoints. For adults initially with stage T3 HCC who received LRT, there were three studies reporting on transplant with any down-staging therapy versus no downstaging, and this showed a significant increase in 1-year (two studies, RR, 1.11; 95% CI, 1.01-1.23) and 5-year (1 study, RR, 1.17; 95% CI, 1.03-1.32) post-LT survival rates for patients who received LRT. The quality of evidence is very low due to serious risk of bias and imprecision. CONCLUSION: In patients with HCC listed for LT, the use of LRT is associated with a nonsignificant trend toward improved waitlist and posttransplant outcomes, though there is a high risk of selection bias in the available evidence. (Hepatology 2018;67:381-400).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology. 2017. PMID: 28859222. doi:10.1002/hep.29485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。